Digital health startup Ro now prescribes recently approved weight loss drug Zepbound

A digital health startup is jumping in to offer the latest weight loss drug approved by the FDA.

Ro, a startup that prescribes and ships medication directly to customers, is adding tirzepatide to its list of weight loss medication offerings, the company announced on Wednesday. The Eli Lilly drug was approved for weight management last month with the marketing name Zepbound.

“Zepbound is poised to be the most impactful anti-obesity medication we’ve seen so far in our lifetime,” Ro’s chief medical officer Dr. Melynda Barnes said in a statement.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。